With a given nAMD understanding as a VEGF-induced vasculopathy,2,3,27–29 this might explain why patients in our cohort with quantitatively higher saccharin blood levels achieve better suppression of their CNV under treatment. The gene discussed is VEGFA; the disease is vascular disorder.